PEG-MGFUnderstand the science
How a sports classification differs from a clinical finding
2 numbered sourcesSource years 2025, 2026
Peptides are short strings of amino acids held together by peptide bonds. Some help coordinate growth and tissue responses. PEG-MGF is a synthetic MGF-related peptide with a polyethylene glycol group attached. Its name refers to mechano growth factor research in the IGF-I family. The 2026 anti-doping list names mechano growth factors as a class, which raises a question about what a class listing establishes and what remains a question for clinical research. [1, 2]
The World Anti-Doping Agency list took effect on January 1, 2026. It places mechano growth factors under growth factors and growth factor modulators in section S2.3. The broader section describes substances prohibited both in and out of competition and includes related substances within its stated scope. The wording is organized by classes and named examples. The class entry identifies mechano growth factors collectively, while FDA’s compounding safety record discusses PEG-MGF by its specific name. [1, 2]
These sources serve different purposes. The anti-doping list defines the rules applied under the World Anti-Doping Code. It is a statement about the scope of that system. FDA’s record asks what evidence exists about a nominated bulk drug substance and what risks that evidence can characterize. FDA reported that it had identified no human exposure data for PEG-MGF. Neither the classification nor the human evidence gap gives a measure of how the material would affect performance. [1, 2]
The differences are easy to miss when the two records appear together in a search. Both may mention growth factor biology, yet one identifies a group of substances for sports governance and the other addresses evidence for a specific substance. The meaning of each record comes from the question it was written to answer. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
